Shares of Curis, Inc. (NASDAQ:CRIS) rose 6% during trading on Monday . The company traded as high as $1.83 and last traded at $1.77, with a volume of 1,112,510 shares. The stock had previously closed at $1.67.

CRIS has been the topic of a number of recent research reports. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Cowen and Company restated a “buy” rating on shares of Curis in a research note on Monday, May 15th. BidaskClub downgraded Curis from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, ValuEngine upgraded Curis from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $5.88.

The firm’s market cap is $263.30 million. The stock has a 50-day moving average price of $1.85 and a 200 day moving average price of $2.19.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.01. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The company had revenue of $2.10 million for the quarter, compared to analyst estimates of $2.08 million. During the same quarter in the prior year, the business earned ($0.09) EPS. Curis’s revenue was up 23.5% compared to the same quarter last year. Analysts forecast that Curis, Inc. will post ($0.40) EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of CRIS. The Manufacturers Life Insurance Company raised its position in Curis by 8.8% in the second quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock worth $190,000 after buying an additional 8,102 shares in the last quarter. State Street Corp boosted its stake in shares of Curis by 10.4% in the second quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock worth $3,511,000 after buying an additional 175,424 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Curis by 4.9% in the second quarter. Royal Bank of Canada now owns 956,717 shares of the biotechnology company’s stock worth $1,808,000 after buying an additional 44,421 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Curis by 1.6% in the second quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock worth $226,000 after buying an additional 1,880 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in shares of Curis by 21.8% in the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after buying an additional 12,207 shares during the last quarter. Institutional investors and hedge funds own 50.94% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Curis, Inc. (CRIS) Stock Price Up 6%” was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/30/curis-inc-cris-stock-price-up-6-2.html.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.